Structure–Activity Relationships of the MEPicides: N‑Acyl and O‑Linked Analogs
of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis
posted on 2016-09-27, 00:00authored byGéraldine San Jose, Emily R. Jackson, Amanda Haymond, Chinchu Johny, Rachel
L. Edwards, Xu Wang, R. Carl Brothers, Emma K. Edelstein, Audrey R. Odom, Helena I. Boshoff, Robin D. Couch, Cynthia S. Dowd
Despite continued research efforts,
the threat of drug resistance from a variety of bacteria continues
to plague clinical communities. Discovery and validation of novel
biochemical targets will facilitate development of new drugs to combat
these organisms. The methylerythritol phosphate (MEP) pathway to make
isoprene units is a biosynthetic pathway essential to many bacteria.
We and others have explored inhibitors of the MEP pathway as novel
antibacterial agents. Mycobacterium tuberculosis,
the causative agent of tuberculosis, and Yersinia pestis, resulting in the plague or “black death”, both rely
on the MEP pathway for isoprene production. 1-Deoxy-d-xylulose
5-phosphate reductoisomerase (Dxr) catalyzes the first committed step
in the MEP pathway. We examined two series of Dxr inhibitors based
on the parent structure of the retrohydroxamate natural product FR900098.
The compounds contain either an extended N-acyl or O-linked alkyl/aryl group and are designed to act as bisubstrate
inhibitors of the enzyme. While nearly all of the compounds inhibited
both Mtb and Yp Dxr to some extent, compounds generally displayed
more potent inhibition against the Yp homologue, with the best analogs
displaying nanomolar IC50 values. In bacterial growth inhibition
assays, the phosphonic acids generally resulted in poor antibacterial
activity, likely a reflection of inadequate permeability. Accordingly,
diethyl and dipivaloyloxymethyl (POM) prodrug esters of these compounds
were made. While the added lipophilicity did not enhance Yersinia activity, the compounds showed significantly improved antitubercular
activities. The most potent compounds have Mtb MIC values of 3–12
μg/mL. Taken together, we have uncovered two series of analogs
that potently inhibit Dxr homologues from Mtb and Yp. These inhibitors
of the MEP pathway, termed MEPicides, serve as leads for future analog
development.